MarketCap
Facebook
X
TelegramQuartalsbericht 2024-Q1
hinzugefügt 14.05.2024
Acorda Therapeutics Operativer Cashflow 2011-2025 | ACOR
Operativer Cashflow Jährlich Acorda Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -14 M | -20.9 M | -41.3 M | -61 M | -128 M | 151 M | 97.1 M | 29.6 M | - | - | - | - | 66.3 M |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 151 M | -128 M | 8.72 M |
Operativer Cashflow Vierteljährlich Acorda Therapeutics
| 2024-Q1 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -20.2 M | -7.02 M | - | -30 M | -28.2 M | -13.6 M | - | -44.6 M | -35.6 M | -26.9 M | - | -62.5 M | -59.5 M | -38.8 M | - | -117 M | -92.4 M | -77.5 M | - | 163 M | 85 M | 28.7 M | - | 36.6 M | -15.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -12.1 M |
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 163 M | -117 M | -18.4 M |
Operativer Cashflow anderer Aktien in der Pharmaeinzelhändler
| Name | Operativer Cashflow | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
ARCA biopharma
ABIO
|
-57.8 M | - | 1052.0 % | $ 415 M |  USA |
 |
Amphastar Pharmaceuticals
AMPH
|
213 M | $ 25.27 | -2.43 % | $ 1.22 B | USA |
 |
MorphoSys AG
MOR
|
-481 M | - | 2.43 % | $ 254 M |  Germany |
 |
Alpine Immune Sciences
ALPN
|
-43.8 M | - | - | $ 2.17 B | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
-85.9 M | $ 4.75 | 1.61 % | $ 788 M |  Canada |
 |
Aclaris Therapeutics
ACRS
|
-20.1 M | $ 3.26 | -3.12 % | $ 252 M | USA |
 |
AlloVir
ALVR
|
-67.7 M | - | 4.14 % | $ 49.1 M | USA |
 |
Acasti Pharma
ACST
|
-14.9 M | - | 4.01 % | $ 150 M | Canada |
 |
Adaptimmune Therapeutics plc
ADAP
|
-141 M | - | -15.15 % | $ 60.3 M |  Britain |
 |
Ampio Pharmaceuticals
AMPE
|
-8.56 M | - | -11.43 % | $ 502 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-157 M | - | - | $ 1.01 B | USA |
 |
Kamada Ltd.
KMDA
|
-8.82 M | $ 7.03 | 0.14 % | $ 260 M |  Israel |
 |
Ascendis Pharma A/S
ASND
|
-418 M | $ 220.27 | 4.81 % | $ 5 B |  Danmark |
 |
Albireo Pharma
ALBO
|
-108 M | - | -0.23 % | $ 916 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-34.5 M | - | - | $ 7.46 M | Israel |
 |
Enlivex Therapeutics Ltd.
ENLV
|
-13 M | $ 0.91 | -5.01 % | $ 18.7 M | Israel |
 |
Can-Fite BioPharma Ltd.
CANF
|
-7.64 M | $ 0.28 | -2.28 % | $ 609 M | Israel |
 |
Alterity Therapeutics Limited
ATHE
|
-12.3 M | $ 3.3 | -3.51 % | $ 7.94 B |  Australia |
 |
AstraZeneca PLC
AZN
|
5.96 B | $ 89.78 | -0.57 % | $ 96.9 B | Britain |
 |
Midatech Pharma plc
MTP
|
-6.01 M | - | -18.52 % | $ 27.3 M | Britain |
 |
Anika Therapeutics
ANIK
|
-1.79 M | $ 9.57 | 0.84 % | $ 140 M | USA |
 |
Brickell Biotech
BBI
|
-4.34 M | - | -5.38 % | $ 6.06 M | USA |
 |
BeiGene, Ltd.
BGNE
|
-141 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Bellicum Pharmaceuticals
BLCM
|
-25.8 M | - | -9.72 % | $ 5.89 M | USA |
 |
Berkeley Lights
BLI
|
-47.5 M | - | -7.31 % | $ 87 M | USA |
 |
Benitec Biopharma
BNTC
|
-23.6 M | $ 12.05 | -7.06 % | $ 496 M | USA |
 |
Aytu BioScience
AYTU
|
-1.94 M | $ 2.34 | 2.59 % | $ 14.7 M | USA |
 |
Nymox Pharmaceutical Corporation
NYMX
|
-9.82 M | - | -19.68 % | $ 18.4 M | Canada |
 |
Arena Pharmaceuticals
ARNA
|
-452 M | - | -6.81 % | $ 3.04 B | USA |
 |
Aptorum Group Limited
APM
|
-1.19 M | $ 1.29 | -3.01 % | $ 7.03 M |  China |
 |
Biophytis SA
BPTS
|
-23.8 M | - | -13.47 % | $ 169 M |  France |
 |
Baudax Bio
BXRX
|
-27.8 M | - | 0.59 % | $ 63 K | USA |
 |
Avenue Therapeutics
ATXI
|
-9.03 M | - | -52.27 % | $ 4.45 M | USA |
 |
Catalyst Biosciences
CBIO
|
25.9 M | $ 14.01 | -8.49 % | $ 922 M | USA |
 |
ChromaDex Corporation
CDXC
|
12.1 M | - | -0.88 % | $ 598 M | USA |
 |
Axon Enterprise
AXON
|
408 M | $ 566.18 | -2.56 % | $ 42.9 B | USA |
 |
Cerus Corporation
CERS
|
11.4 M | $ 2.16 | 0.47 % | $ 399 M | USA |
 |
Checkpoint Therapeutics
CKPT
|
-31.1 M | - | - | $ 169 M | USA |
 |
Caladrius Biosciences
CLBS
|
-19.4 M | - | -16.75 % | $ 25.8 M | USA |
 |
Clovis Oncology
CLVS
|
-196 M | - | -7.23 % | $ 13 M | USA |
 |
Biogen
BIIB
|
2.88 B | $ 174.42 | 1.11 % | $ 25.4 B | USA |
 |
BioVie
BIVI
|
-19 M | $ 1.42 | -5.96 % | $ 2.1 M | USA |
 |
Celldex Therapeutics
CLDX
|
-158 M | $ 27.36 | -2.09 % | $ 1.76 M | USA |
 |
Cortexyme
CRTX
|
-18.3 M | - | -1.05 % | $ 67.1 M | USA |
 |
Cellectar Biosciences
CLRB
|
-32.4 M | $ 3.63 | -3.97 % | $ 44.4 M | USA |
 |
Deciphera Pharmaceuticals
DCPH
|
-147 M | - | - | $ 2.18 B | USA |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
-831 M | $ 11.54 | 0.87 % | $ 746 M | USA |